Windels Marx Lane & Mittendorf competitors

PROFESSIONAL PROFILE: LEADERSHIP AND EXPERIENCEI have substantial experience in the HE sector at the highest levels of senior management both through my present appointment as Senior Vice-President (Global) and in my previous roles of Acting Deputy Vice-Chancellor (Research and Innovation) and Pro Vice-Chancellor (International relations) at the University of Surrey. Prior to joining Surrey in September 2012, during my tenure at UCL I was a significant contributor to the senior management team of the School of Life and Medical Sciences and Faculty of Biomedical Sciences and a major lead on quality assurance (in both teaching and learning and research) for the University. I also spearheaded our regional engagement programme through my role as a Pro-Provost. Most of my roles require, or have required, significant diplomatic skills and an ability to lead multidisciplinary complex teams in order to deliver the desired outcomes without the individuals necessarily being under my direct line management. Effective communication and ability to articulate a vision has been instrumental in achieving success together with effective use of networks of key individuals to deliver strategies . I am well versed in leading significant organisational change through engagement and persuasion. I regularly speak at Higher Education, research and International Summits in the UK and globally relating to research led teaching, building academic links with Asia, opportunities for educational development between the UK and other countries and university governance and management of strategic international developments. I sit or have sat on advisory boards for a range of Biotech and large Pharma companies including Roche, Novartis, MSD, Janssen, Johnsons and Johnson and also SMEs in the biotech sector. I have also undertaken medico-legal work as an advisor/witness for both defence and prosecution cases relating to organ transplantation and infectious diseases.

From the Boston office of Nixon Peabody, I lead 1,500 colleagues, including more than 650 attorneys who collaborate across practice areas in cities throughout the U.S. and with alliance firms around the world. I have a background in business, and I cultivate an entrepreneurial culture at our firm. I’ve been with Nixon Peabody since 1987 and before I took my current role of CEO and managing partner, I served as managing partner of the Boston office. Building and leading teams is my passion-both as an attorney representing clients in structuring successful and creative transactions and resolving business and real estate disputes and now in my role as leader of Nixon Peabody. And, over my career, I’ve served as a mentor and advisor to many, and take great pride in helping my colleagues succeed. While I’m in an industry that relies on precedent, I’m focused on building the law firm of the future and how we can channel collaboration and innovation to stay on top of industry trends and provide the insights and connections that help our clients succeed. I also strongly believe in giving back to the community where I work and live, and focus my efforts on youth and seniors. I’ve been a volunteer for more than three decades at Hebrew Senior Life, which provides medical and housing services for the elderly, serving in numerous roles including as chairman of the board. I also taught real estate finance for 23 years at Boston College.

Mark Ruehlmann is a Chairman/CEO:Global at Squire Patton Boggs. He has worked as Partner at Squire Patton Boggs. Mark studied at Gamma Beta Phi Society, University Of Notre - Dam Do Lek, and University of Notre Dame.

Chair the firm’s management committee and responsible for its strategic direction. Banking and structured finance lawyer. Represent ABCP conduit sponsors, bank lenders and providers of credit enhancement and liquidity facilities to corporate and municipal securities. Significant experience with bank regulatory issues affecting securitizations. Frequent speaker and writer on bank regulatory issues affecting securitizations. Have written industry comment letters on several securitization regulatory topics including the risk-based capital rules, risk retention, the Volcker Rule, the liquidity coverage ratio and the net stable funding ratio.